S&P 500   4,519.63 (+0.74%)
DOW   35,457.31 (+0.56%)
QQQ   375.86 (+0.86%)
AAPL   148.80 (+1.54%)
MSFT   308.59 (+0.42%)
FB   340.10 (+1.42%)
GOOGL   2,865.08 (+0.33%)
TSLA   865.29 (-0.55%)
AMZN   3,444.58 (-0.06%)
NVDA   223.10 (+0.40%)
BABA   177.02 (+6.11%)
NIO   39.98 (+0.93%)
CGC   14.36 (+8.79%)
GE   104.71 (+0.57%)
AMD   116.26 (-0.15%)
MU   67.57 (+0.46%)
T   25.56 (+0.91%)
F   15.42 (-0.90%)
ACB   7.45 (+7.66%)
DIS   171.10 (-0.02%)
PFE   42.12 (+1.94%)
BA   215.81 (-0.54%)
AMC   40.75 (-5.30%)
S&P 500   4,519.63 (+0.74%)
DOW   35,457.31 (+0.56%)
QQQ   375.86 (+0.86%)
AAPL   148.80 (+1.54%)
MSFT   308.59 (+0.42%)
FB   340.10 (+1.42%)
GOOGL   2,865.08 (+0.33%)
TSLA   865.29 (-0.55%)
AMZN   3,444.58 (-0.06%)
NVDA   223.10 (+0.40%)
BABA   177.02 (+6.11%)
NIO   39.98 (+0.93%)
CGC   14.36 (+8.79%)
GE   104.71 (+0.57%)
AMD   116.26 (-0.15%)
MU   67.57 (+0.46%)
T   25.56 (+0.91%)
F   15.42 (-0.90%)
ACB   7.45 (+7.66%)
DIS   171.10 (-0.02%)
PFE   42.12 (+1.94%)
BA   215.81 (-0.54%)
AMC   40.75 (-5.30%)
S&P 500   4,519.63 (+0.74%)
DOW   35,457.31 (+0.56%)
QQQ   375.86 (+0.86%)
AAPL   148.80 (+1.54%)
MSFT   308.59 (+0.42%)
FB   340.10 (+1.42%)
GOOGL   2,865.08 (+0.33%)
TSLA   865.29 (-0.55%)
AMZN   3,444.58 (-0.06%)
NVDA   223.10 (+0.40%)
BABA   177.02 (+6.11%)
NIO   39.98 (+0.93%)
CGC   14.36 (+8.79%)
GE   104.71 (+0.57%)
AMD   116.26 (-0.15%)
MU   67.57 (+0.46%)
T   25.56 (+0.91%)
F   15.42 (-0.90%)
ACB   7.45 (+7.66%)
DIS   171.10 (-0.02%)
PFE   42.12 (+1.94%)
BA   215.81 (-0.54%)
AMC   40.75 (-5.30%)
S&P 500   4,519.63 (+0.74%)
DOW   35,457.31 (+0.56%)
QQQ   375.86 (+0.86%)
AAPL   148.80 (+1.54%)
MSFT   308.59 (+0.42%)
FB   340.10 (+1.42%)
GOOGL   2,865.08 (+0.33%)
TSLA   865.29 (-0.55%)
AMZN   3,444.58 (-0.06%)
NVDA   223.10 (+0.40%)
BABA   177.02 (+6.11%)
NIO   39.98 (+0.93%)
CGC   14.36 (+8.79%)
GE   104.71 (+0.57%)
AMD   116.26 (-0.15%)
MU   67.57 (+0.46%)
T   25.56 (+0.91%)
F   15.42 (-0.90%)
ACB   7.45 (+7.66%)
DIS   171.10 (-0.02%)
PFE   42.12 (+1.94%)
BA   215.81 (-0.54%)
AMC   40.75 (-5.30%)
NASDAQ:NUVL

Nuvalent Stock Forecast, Price & News

$21.15
+0.28 (+1.34 %)
(As of 10/19/2021 03:59 PM ET)
Add
Compare
Today's Range
$20.47
$22.48
50-Day Range
$18.01
$38.35
52-Week Range
$17.00
$40.82
Volume2,314 shs
Average Volume195,550 shs
Market Capitalization$1.02 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive NUVL News and Ratings via Email

Sign-up to receive the latest news and ratings for Nuvalent and its competitors with MarketBeat's FREE daily newsletter.


Nuvalent logo

About Nuvalent

Nuvalent Inc. is a biopharmaceutical company. It focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. The company's program pipeline includes ROS1-positive and ALK-positive NSCLC. Nuvalent Inc. is based in CAMBRIDGE, Mass.

Headlines

Nuvalent (NASDAQ:NUVL) Trading Up 6.8%
October 19, 2021 |  americanbankingnews.com
Nuvalent (NASDAQ:NUVL) Shares Gap Up to $19.93
October 18, 2021 |  americanbankingnews.com
Short Interest in Nuvalent Inc (NASDAQ:NUVL) Increases By 48.8%
October 17, 2021 |  americanbankingnews.com
Nuvalent (NASDAQ:NUVL) Stock Price Down 4.6%
October 15, 2021 |  americanbankingnews.com
Nuvalent (NASDAQ:NUVL) Shares Gap Down to $18.01
October 12, 2021 |  americanbankingnews.com
Nuvalent, Inc. (NUVL)
October 7, 2021 |  finance.yahoo.com
Nuvalent (NASDAQ:NUVL) Shares Down 5%
October 7, 2021 |  americanbankingnews.com
Nuvalent Inc (NASDAQ:NUVL) Short Interest Update
October 6, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NUVL
Phone
N/A
Employees
2,021
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$1.02 billion
Next Earnings Date
12/8/2021 (Estimated)
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.70 out of 5 stars

Medical Sector

903rd out of 1,361 stocks

Pharmaceutical Preparations Industry

443rd out of 668 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Nuvalent (NASDAQ:NUVL) Frequently Asked Questions

Is Nuvalent a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nuvalent in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Nuvalent stock.
View analyst ratings for Nuvalent
or view top-rated stocks.

What stocks does MarketBeat like better than Nuvalent?

Wall Street analysts have given Nuvalent a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Nuvalent wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Nuvalent?

Nuvalent saw a increase in short interest in September. As of September 30th, there was short interest totaling 1,440,000 shares, an increase of 48.8% from the September 15th total of 967,700 shares. Based on an average daily volume of 251,000 shares, the short-interest ratio is presently 5.7 days. Currently, 3.9% of the shares of the company are short sold.
View Nuvalent's Short Interest
.

When is Nuvalent's next earnings date?

Nuvalent is scheduled to release its next quarterly earnings announcement on Wednesday, December 8th 2021.
View our earnings forecast for Nuvalent
.

How were Nuvalent's earnings last quarter?

Nuvalent Inc (NASDAQ:NUVL) released its quarterly earnings results on Wednesday, September, 8th. The company reported ($3.17) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by $2.97.
View Nuvalent's earnings history
.

What price target have analysts set for NUVL?

3 equities research analysts have issued 12 month target prices for Nuvalent's shares. Their forecasts range from $34.00 to $40.00. On average, they expect Nuvalent's stock price to reach $37.00 in the next twelve months. This suggests a possible upside of 74.9% from the stock's current price.
View analysts' price targets for Nuvalent
or view top-rated stocks among Wall Street analysts.

When did Nuvalent IPO?

(NUVL) raised $151 million in an initial public offering (IPO) on Thursday, July 29th 2021. The company issued 8,900,000 shares at $16.00-$18.00 per share.

What is Nuvalent's stock symbol?

Nuvalent trades on the NASDAQ under the ticker symbol "NUVL."

When did Nuvalent's quiet period expire?

Nuvalent's quiet period expired on Tuesday, September 7th. Nuvalent had issued 9,150,000 shares in its IPO on July 29th. The total size of the offering was $155,550,000 based on an initial share price of $17.00. During Nuvalent's quiet period, insiders and underwriters involved in the IPO were prevented from issuing any earnings forecasts or research reports for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of Nuvalent?

Shares of NUVL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nuvalent's stock price today?

One share of NUVL stock can currently be purchased for approximately $21.15.

How much money does Nuvalent make?

Nuvalent has a market capitalization of $1.02 billion.

How many employees does Nuvalent have?

Nuvalent employs 2,021 workers across the globe.

What is Nuvalent's official website?

The official website for Nuvalent is www.nuvalent.com.


This page was last updated on 10/19/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.